Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors

समान संसाधन

• Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1
  द्वारा: Razanamahery, Jérôme, और अन्य
  प्रकाशित: (2020)
• Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease
  द्वारा: Emile, Jean-François, और अन्य
  प्रकाशित: (2014)
• Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease
  द्वारा: Ferrero, Elisabetta, और अन्य
  प्रकाशित: (2016)
• Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
  द्वारा: Saunders, Ila M., और अन्य
  प्रकाशित: (2019)
• The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim–Chester Disease
  द्वारा: Weissman, Ran, और अन्य
  प्रकाशित: (2020)